Imatinib-ULS-lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases
M. Emmy M. Dolman(Cancer Institute of New South Wales), Robbert J. Kok(Utrecht University), G. Storm(Utrecht University), Kim M. A. van Dorenmalen(Utrecht University), M. Lacombe(Université du Québec à Rimouski), János Pató(Vichem Chemie (Hungary)), E. Pieters(Utrecht University), Wim E. Hennink(Utrecht University)
Cited by 32
Related Papers
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
|Nature Genetics|2015|563
Tumour-targeted nanomedicines: principles and practice
|British Journal of Cancer|2008|535
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
|Advanced Drug Delivery Reviews|2013|396
Diverse origins of the myofibroblast—implications for kidney fibrosis
|Nature Reviews Nephrology|2015|305